Amgen (AMGN) Share-based Compensation Growth (1y) (2010 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Stock Comp. Growth (1y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
4.55% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
4.17% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
8.29% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-5.13% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-11.76% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
4.31% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
60.00% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
1.39% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
-11.76% |
| Dec 31, 2025 |
-6.72% |
| Sep 30, 2025 |
-6.62% |
| Jun 30, 2025 |
0.00% |
| Mar 31, 2025 |
-17.48% |
| Dec 31, 2024 |
-16.77% |
| Sep 30, 2024 |
30.77% |
| Jun 30, 2024 |
31.93% |
| Mar 31, 2024 |
119.15% |
| Dec 31, 2018 |
2.35% |
| Sep 30, 2018 |
-12.50% |
| Jun 30, 2018 |
-3.13% |
| Mar 31, 2018 |
-10.00% |
| Dec 31, 2017 |
-4.49% |
| Sep 30, 2017 |
6.02% |
| Jun 30, 2017 |
10.34% |
| Mar 31, 2017 |
15.38% |
| Dec 31, 2016 |
11.25% |
| Sep 30, 2016 |
1.22% |
| Jun 30, 2016 |
-3.33% |
| Mar 31, 2016 |
-25.71% |
| Dec 31, 2015 |
-24.53% |
| Sep 30, 2015 |
-20.39% |
| Jun 30, 2015 |
-19.64% |
| Mar 31, 2015 |
-19.54% |
| Dec 31, 2014 |
7.07% |
| Sep 30, 2014 |
3.00% |
| Jun 30, 2014 |
0.00% |
| Mar 31, 2014 |
-5.43% |
| Dec 31, 2013 |
8.79% |
| Sep 30, 2013 |
9.89% |
| Jun 30, 2013 |
6.67% |
| Mar 31, 2013 |
22.67% |
| Dec 31, 2012 |
-5.21% |
| Sep 30, 2012 |
28.17% |
| Jun 30, 2012 |
8.25% |
| Mar 31, 2012 |
-2.60% |
| Dec 31, 2011 |
-8.57% |
| Sep 30, 2011 |
-13.41% |
| Jun 30, 2011 |
-1.02% |
| Mar 31, 2011 |
13.24% |
| Dec 31, 2010 |
40.00% |
| Sep 30, 2010 |
-4.65% |
| Jun 30, 2010 |
53.13% |
| Mar 31, 2010 |
15.25% |